Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 clients • 6 examiners • 6 art units • 0 of 6 (0%) have an AI response strategy ready
COVINGTON & BURLING, LLP operates in the Biotechnology & Pharmaceuticals technology area, with 586 career applications. The firm currently manages 6 pending office actions, reflecting their active role in the patent process. This career total of 586 applications establishes their experience in Biotechnology & Pharmaceuticals. The 6 pending office actions are a current measure of their prosecution work.
The firm maintains a resolved allowance rate of 64.19 percent, a metric calculated from their 586 career applications. This 64.19 percent rate indicates the firm's success in achieving patent grants. Prosecution requires an average of 3.26 office actions per allowance. For practitioners, this 3.26 average provides a clear expectation for the number of examiner interactions. The 6 pending office actions are managed alongside this 64.19 percent allowance rate and 3.26 office action average. These figures collectively describe the firm's historical performance and current engagement in their primary technology area.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (50%) |
| §102 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMANI, NILOOFAR | 1 | 77.5% | -2.9% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
| TORRES, ALICIA M | 1 | 73.5% | +17.5% |
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
| RAMOS LEWIS, JOSMALEN MILAGROS | 1 | 53.6% | +23.9% |
| SONG, JIANFENG | 1 | 56.3% | +33.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17639489 | EXTENDED RELEASE DOSAGE FORMS FOR TYK2 INHIBITORS | RAMOS LEWIS, JOSMALEN MILAGROS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18276837 | SINGLE OPERATOR SEED PLANTING APPARATUSES, SYSTEMS, AND METHODS OF USE | TORRES, ALICIA M | 121d overdue |
| 18026704 | DOSAGE FORMS FOR TYK2 INHIBITORS COMPRISING SWELLABLE CORES | WELLS, LAUREN QUINLAN | 26d overdue |
| 18684747 | CRYSTAL FORMS OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3- (1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE | CHANDRAKUMAR, NIZAL S | — |
| 17639489 | EXTENDED RELEASE DOSAGE FORMS FOR TYK2 INHIBITORS | RAMOS LEWIS, JOSMALEN MILAGROS | — |
| 17627112 | COMPOSITION AND METHOD OF TREATING BACTERIAL AND VIRAL PATHOGENS IN PLANTS | SONG, JIANFENG | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Bristol-Myers Squibb | 4 |
| Brooklyn Bridge to Cambodia | 1 |
| Greening Be Gone, LLC | 1 |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1625 | 1 |
| 3671 | 1 |
| 1622 | 1 |
| 1621 | 1 |
| 1613 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18694424 | METHODS OF TREATING HAIR-LOSS DISORDERS WITH TYK2 INHIBITORS | Bristol-Myers Squibb Company | RAHMANI, NILOOFAR | 1691 | §102 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18684747 | CRYSTAL FORMS OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3- (1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE | Bristol-Myers Squibb Company | CHANDRAKUMAR, NIZAL S | 1625 | §103DP | Non-Final OA | — | Pending | Feb 19, 2024 |
| 18276837 | SINGLE OPERATOR SEED PLANTING APPARATUSES, SYSTEMS, AND METHODS OF USE | Brooklyn Bridge To Cambodia, Inc. | TORRES, ALICIA M | 3671 | §103 | Final Rejection | 121d overdue | Pending | Aug 10, 2023 |
| 18026704 | DOSAGE FORMS FOR TYK2 INHIBITORS COMPRISING SWELLABLE CORES | Bristol-Myers Squibb Company | WELLS, LAUREN QUINLAN | 1622 | §103 | Final Rejection | 26d overdue | Pending | Mar 16, 2023 |
| 17639489 | EXTENDED RELEASE DOSAGE FORMS FOR TYK2 INHIBITORS | Bristol-Myers Squibb Company | RAMOS LEWIS, JOSMALEN MILAGROS | 1621 | §103§112 | Final Rejection | — | Pending | Mar 01, 2022 |
| 17627112 | COMPOSITION AND METHOD OF TREATING BACTERIAL AND VIRAL PATHOGENS IN PLANTS | Greening Be Gone, LLC | SONG, JIANFENG | 1613 | §103 | Final Rejection | — | Pending | Jan 13, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial